ClinicalTrials.gg
CompletedNCT06170723Updated Jul 1, 2024

A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants

A Phase 1 interventional study of BMS-986368 and Itraconazole in Healthy Participants, sponsored by Celgene. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This 2-part study will evaluate the effect of coadministration of a Cytochrome P450, family 3, subfamily A (CYP3A) inhibitor, itraconazole (Part 1), and a high-fat/high-calorie meal and a modified gastric pH (Part 2), on the single dose drug levels of BMS-986368 in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • BMS-986368
  • Itraconazole
  • Famotidine
  • Food Effect
  • Healthy Volunteers
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18.0 kilograms per meter squared (kg/m\^2) to 33.0 kg/m\^2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Personal or first-degree family history of psychiatric disorder, including, but not limited to, schizophrenia, psychosis, bipolar disorder, generalized anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. Situational depression, or anxiety in the past, may be enrolled at the discretion of the investigator.
  • Participant has an active or prior history of stroke, chronic seizures, or major neurological disorders or has first-degree family relative who was diagnosed with these disorders below the age of 65 years.
  • Participant has a history of syncope and/or symptomatic orthostatic hypotension in the year prior to Day 1.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Part 1: BMS-986368 - Fasted

    Drug: BMS-986368

  • Experimental
    Part 1: Itraconazole - Fasted

    Drug: Itraconazole

  • Experimental
    Part 1: BMS-986368 with Itraconazole - Fasted

    Drug: BMS-986368 · Drug: Itraconazole

  • Experimental
    Part 2: BMS-986368 - Fasted

    Drug: BMS-986368

  • Experimental
    Part 2: BMS-986368 - Fed

    Drug: BMS-986368

  • Experimental
    Part 2: Famotidine, followed by BMS-986368 - Fasted

    Drug: BMS-986368 · Drug: Famotidine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 11 days

  2. Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])

    Time frame: Up to 11 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])

    Time frame: Up to 11 days

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 41 days

  2. Number of participants with physical examination abnormalities

    Time frame: Up to 17 days

  3. Number of participants with vital sign abnormalities

    Time frame: Up to 17 days

  4. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 17 days

  5. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 17 days

  6. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to 17 days

07

Study locations

1 site
  • Local Institution - 0001
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in May 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 14, 2023
StartActual
Mar 18, 2024
Primary completionActual
May 25, 2024
CompletionActual
May 25, 2024
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06170723
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Mar 18, 2024
Primary completion
May 25, 2024
Completion
May 25, 2024
Last update
Jul 1, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irafamdastat · Itraconazole

Start the discussion